OriGene Logo

Customer Login

Checkout as a new customer

Creating an account has many benefits:

  • See order and shipping status
  • Track order history
  • Check out faster
Create an Account

HCV Envelope glycoprotein E1 Mouse Monoclonal Antibody [Clone ID: BDI198]

Be the first to review this product
SKU
BM3324
HCV Envelope glycoprotein E1 mouse monoclonal antibody, clone BDI198, Purified
Size:
100 ug
Conjugation:
Unconjugated
  $1,435.00
2 Weeks*
Bulk/Customize

View other "E1" antibodies

Specifications
Specifications
Product Data
Clone Name BDI198
Application ELISA, IF, IHC, WB
Recommended Dilution IFA.
ELISA.
Western blot.
Immunohistochemistry.
Reactivity Hepatitis C Virus
Antibody Host Mouse
Isotype IgG
Clonality Monoclonal
Immunogen Recombinant HCV E1 glycoprotein (genotype 1b).
Specificity Specific to HCV E1.
Buffer 0.01M PBS, pH 7.2 containing 0.09% Sodium Azide as preservative without stabilizing proteins
State: Purified
State: Liquid purified Ig fraction from Ascites (> 90% pure)
Concentration lot specific
Purification Protein A Chromatography
Conjugation Unconjugated
Storage Upon receipt, store (in aliquots) at -20°C.
Avoid repeated freezing and thawing.
Stability Shelf life: one year from despatch.
Shipping Blue Ice
Background Envelope glycoproteins E1 and E2 are involved in virus attachment to the host cell as well as in virus endocytosis and fusion with host membrane. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs are professional antigen presenting cells, critical for host immunity by inducing specific immune responses against a broad variety of pathogens. They act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection.
Synonyms Heptitis C Virus E1, gp32, gp35
Reference Data
Reviews
Write Review
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

Enhancing Hepatitis C Virus pseudoparticles infectivity through p7NS2 cellular expression
Soares, Ferreira-Fernandes, Almeida et al
J. Virol. Methods (2019) 274, 113714 DOI: 10.1016/j.jviromet.2019.113714
AI Summary: The paper "Enhancing Hepatitis C Virus pseudoparticles infectivity through p7NS2 cellular expression" utilized the TrueORF cDNA clone for p7NS2 from OriGene to achieve stable overexpression of p7NS2, which significantly contributed to the observed enhancement in HCV pseudoparticle infectivity.
Snippet: clone 4B10 (Cell Signaling Technology, Danvers, USA), rabbit anti-β-Galactosidase (Thermo Fisher Scientific Inc, Waltham, USA), mouse anti-β-Tubulin antibody (Santa Cruz, Dallas, USA), mouse monoclonal antibodies anti-HCV E1 (Acris Antibodies, Herford, Germany;;- clone 4B10 (Cell Signaling Technology, Danvers, USA), rabbit anti-β-Galactosidase (Thermo Fisher Scientific Inc, Waltham, USA), mouse anti-β-Tubulin antibody (Santa Cruz, Dallas, USA), mouse monoclonal antibodies anti-HCV E1 (Acris Antibodies, Herford, Germany
WB
Pseudotyping retrovirus like particles vaccine candidates with Hepatitis C virus envelope protein E2 requires the cellular expression of CD81
Soares, Castro, Tomás et al
AMB Express (2019) 9 (1), 22 DOI: 10.1186/s13568-019-0741-5
AI Summary: OriGene products, specifically the TrueORF cDNA clone for human CD81 and the anti-HCV E2 antibody, were used in this study to facilitate the expression and detection of CD81 and HCV E2 proteins, enabling the investigation of CD81's role in the incorporation of HCV E2 into retrovirus-like particles.
Snippet: PVDF membranes were blocked with 4% (w/v) skimmed milk (Merck) and incubated with the respective primary antibody: rabbit anti-CD81 (Sigma-Aldrich), mouse anti-β-Tubulin antibody (SantaCruz, CA, USA), mouse anti-HCV E1 (Acris Antibodies, Herford, Germany
FigureFigureFigure
WB
Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
Marín, Pérez, Gómez et al
Viruses (2018) 10 (8) DOI: 10.3390/v10080414
Cited by 14
AI Summary: In this study, OriGene’s HCV NS3 (cat# TP720617) and HCV Core (cat# TP720634) expression plasmids were used as controls in immunological assays to evaluate vaccine-induced immune responses.
FigureFigureFigure
High-yield production of a chimeric glycoprotein based on permuted E1 and E2 HCV envelope ectodomains
Tello, Rodríguez-Rodríguez, Yélamos et al
J Virol Methods (2015) 213, 38-44 DOI: 10.1016/j.jviromet.2014.11.020
Cited by 7
AI Summary: In this study, OriGene's anti-HCV E2 antibody (Cat# TA503519) was used to assess the antigenic properties of the purified chimeric glycoprotein, helping to confirm its structural similarity to native HCV proteins.
High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome
Gómez, Perdiguero, Cepeda et al
J Virol (2013) 87 (13), 7282-300 DOI: 10.1128/JVI.03246-12
AI Summary: In this study, OriGene products, specifically the HCV gene clone (Cat# SC119688) and the anti-β-actin antibody (Cat# TA-09), were used for constructing the HCV-expressing vector and for protein detection in immunoblot analyses, respectively, thereby supporting the development and evaluation of the novel MVA-HCV vaccine candidate.
Showing 1-5 of 5 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products